ID Biomedical delays study for strep therapy

ID Biomedical has delayed a study on an experimental treatment for strep after the FDA requested more information on the therapy. ID Biomedical added that Canadian regulators have approved a test of a new nasal flu vaccine. "At this time, ID Biomedical is not able to precisely predict how long it may take to generate this data (for StreptAvax) and to what extent additional testing and follow up in adults may be required before obtaining approval to conduct studies in children," the company said in a statement. StreptAvax is designed to fight the bacterium that causes strep throat.

- read this AP report for more

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.